Nan Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nan Yang has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Cheng Fu
Department of Ophthalmology, Margaret M. Dyson Vision Research Institute, Weill Cornell Medicine, New York, USA
1 shared publication- Ching-Hwa Sung
Department of Ophthalmology, Margaret M. Dyson Vision Research Institute, Weill Cornell Medicine, New York, USA
1 shared publication - Daniel Durocher
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada
1 shared publication - David B. Solit
Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
1 shared publication - Elisa de Stanchina
Antitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA
1 shared publication - Gopa Iyer
Memorial Sloan Kettering Cancer Center, New York, USA
1 shared publication
Latest Publications
- Open Access
SLC25A28 is a synthetic lethal vulnerability in nucleotide excision repair-deficient cancers
Approximately 10% of bladder, upper urinary tract, and endometrial cancers harbor deleterious somatic alterations in nucleotide excision repair (NER) pathway genes. Although platinum-based chemotherapy is the standard treatment for NER-deficient tumors, its utility is limited by nephrotoxicity, motivating alternative strategies that avoid direct DNA targeting. Here, we employed a genome-wide CRISPR-Cas9 screen to identify synthetic lethal vulnerabilities in NER-deficient cancer cells. An ERCC4 -null RT112/84 bladder cancer cell line was generated and validated by Sanger sequencing and Western blotting, and functional NER deficiency was confirmed using a host cell reactivation assay. Parallel screens in ERCC4 -deficient and isogenic wild-type cells. nominated SLC25A28 as the top-ranked synthetic lethal candidate in ERCC4 -deficient cells, an interaction further supported by DepMap dependency. Clonogenic assays confirmed that loss of SLC25A28 selectively impaired cell viability in cells deficient for ERCC2 , ERCC3 , ERCC4 , or ERCC5 and inducible knockout selectively suppressed ERCC4 -deficient xenograft growth in-viv o. Mechanistically, RNA sequencing followed by gene set enrichment analysis revealed enrichment of oxidative stress-related pathways, including cellular responses to reactive oxygen species (ROS) and DNA damage signatures, upon SLC25A28 loss. These transcriptional changes are consistent with increased oxidative stress and DNA damage, placing heightened demand on NER-mediated repair. Direct measurement confirmed increased intracellular ROS. Collectively, our nominates SLC25A28 as a previously unrecognized synthetic lethal vulnerability in NER-deficient cancers and implicate mitochondrial iron homeostasis as a candidate metabolic dependency that may be targeted independently of platinum-based chemotherapy. Significance: This study identifies SLC25A28 as a synthetic lethal vulnerability in nucleotide excision repair–deficient cancers, linking mitochondrial iron homeostasis and oxidative stress to selective DNA damage intolerance and therapeutic opportunity.
Open AccessSLC25A28 is a synthetic lethal vulnerability in nucleotide excision repair-deficient cancers
Approximately 10% of bladder, upper urinary tract, and endometrial cancers harbor deleterious somatic alterations in nucleotide excision repair (NER) pathway genes. Although platinum-based chemotherapy is the standard treatment for NER-deficient tumors, its utility is limited by nephrotoxicity, motivating alternative strategies that avoid direct DNA targeting. Here, we employed a genome-wide CRISPR-Cas9 screen to identify synthetic lethal vulnerabilities in NER-deficient cancer cells. An ERCC4 -null RT112/84 bladder cancer cell line was generated and validated by Sanger sequencing and Western blotting, and functional NER deficiency was confirmed using a host cell reactivation assay. Parallel screens in ERCC4 -deficient and isogenic wild-type cells. nominated SLC25A28 as the top-ranked synthetic lethal candidate in ERCC4 -deficient cells, an interaction further supported by DepMap dependency. Clonogenic assays confirmed that loss of SLC25A28 selectively impaired cell viability in cells deficient for ERCC2 , ERCC3 , ERCC4 , or ERCC5 and inducible knockout selectively suppressed ERCC4 -deficient xenograft growth in-viv o. Mechanistically, RNA sequencing followed by gene set enrichment analysis revealed enrichment of oxidative stress-related pathways, including cellular responses to reactive oxygen species (ROS) and DNA damage signatures, upon SLC25A28 loss. These transcriptional changes are consistent with increased oxidative stress and DNA damage, placing heightened demand on NER-mediated repair. Direct measurement confirmed increased intracellular ROS. Collectively, our nominates SLC25A28 as a previously unrecognized synthetic lethal vulnerability in NER-deficient cancers and implicate mitochondrial iron homeostasis as a candidate metabolic dependency that may be targeted independently of platinum-based chemotherapy. Significance: This study identifies SLC25A28 as a synthetic lethal vulnerability in nucleotide excision repair–deficient cancers, linking mitochondrial iron homeostasis and oxidative stress to selective DNA damage intolerance and therapeutic opportunity.
- Open Access
- 23 July 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
Mutant mice with rod-specific VPS35 deletion exhibit retinal α-synuclein pathology-associated degeneration
Vacuolar protein sorting 35 (VPS35), the core component of the retromer complex which regulates endosomal trafficking, is genetically linked with Parkinson’s disease (PD). Impaired vision is a common non-motor manifestation of PD. Here, we show mouse retinas with VPS35-deficient rods exhibit synapse loss and visual deficit, followed by progressive degeneration concomitant with the emergence of Lewy body-like inclusions and phospho-α-synuclein (P-αSyn) aggregation. Ultrastructural analyses reveal VPS35-deficient rods accumulate aggregates in late endosomes, deposited as lipofuscins bound to P-αSyn. Mechanistically, we uncover a protein network of VPS35 and its interaction with HSC70. VPS35 deficiency promotes sequestration of HSC70 and P-αSyn aggregation in late endosomes. Microglia which engulf lipofuscins and P-αSyn aggregates are activated, displaying autofluorescence, observed as bright dots in fundus imaging of live animals, coinciding with pathology onset and progression. The Rod∆Vps35 mouse line is a valuable tool for further mechanistic investigation of αSyn lesions and retinal degenerative diseases.
- 23 July 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
Open AccessMutant mice with rod-specific VPS35 deletion exhibit retinal α-synuclein pathology-associated degeneration
Vacuolar protein sorting 35 (VPS35), the core component of the retromer complex which regulates endosomal trafficking, is genetically linked with Parkinson’s disease (PD). Impaired vision is a common non-motor manifestation of PD. Here, we show mouse retinas with VPS35-deficient rods exhibit synapse loss and visual deficit, followed by progressive degeneration concomitant with the emergence of Lewy body-like inclusions and phospho-α-synuclein (P-αSyn) aggregation. Ultrastructural analyses reveal VPS35-deficient rods accumulate aggregates in late endosomes, deposited as lipofuscins bound to P-αSyn. Mechanistically, we uncover a protein network of VPS35 and its interaction with HSC70. VPS35 deficiency promotes sequestration of HSC70 and P-αSyn aggregation in late endosomes. Microglia which engulf lipofuscins and P-αSyn aggregates are activated, displaying autofluorescence, observed as bright dots in fundus imaging of live animals, coinciding with pathology onset and progression. The Rod∆Vps35 mouse line is a valuable tool for further mechanistic investigation of αSyn lesions and retinal degenerative diseases.
- Open Access
- 1 February 2020
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 145 (2) , AB87
Formononetin Isolated from Ku Shen (Radix Sophorae Flavescentis) Inhibits B cell IgE Production by Inhibiting STAT 6 and NF-κB phosphorylation and XBP1 and IgE heavy chain expression
- 1 February 2020
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 145 (2) , AB87
Open AccessFormononetin Isolated from Ku Shen (Radix Sophorae Flavescentis) Inhibits B cell IgE Production by Inhibiting STAT 6 and NF-κB phosphorylation and XBP1 and IgE heavy chain expression